Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.
GBP2 (F5H3U) Rabbit Monoclonal Antibody #24548
Filter:
- WB
- IP
Product Specifications
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 70 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.
实验步骤
Specificity / Sensitivity
GBP2 (F5H3U) Rabbit mAb recognizes endogenous levels of total GBP2 protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the GTPase domain of human GBP2 protein.
Background
Interferon-gamma (IFN-γ) is an essential molecule for mammalian host defense against intracellular pathogens. Initially uncovered as one of the highest expressed genes after IFN-γ stimulation, guanylate binding protein 2 (GBP2), has been shown to be vital in host immunity against a wide array of bacterial and viral pathogens (1-4).
GBPs are IFN-inducible proteins widely distributed among eukaryotes and are involved in innate immune response and inflammasome activation (3,4). During infection, GBP2 can be localized to pathogen-containing vacuoles and act as a positive regulator of inflammasome assembly. GBP2 promotes lysis of pathogen-containing vacuoles and recruits proteins that mediate bacterial lysis. This process makes ligands available that are detected by inflammasomes, such as lipopolysaccharide (LPS), which activates the non-canonical caspases (through caspase-4 and caspase-11), or double-stranded DNA (dsDNA), which activates inflammasome assembly through AIM2 (5).
In addition to GBP2’s role in immune response, recent work has explored the role of GBP2 in tumor growth and progression (6-8). Increased GBP2 expression is associated with a better prognosis in breast and colon cancers and may result in increased T cell defense against some tumor types (6,7). GBP2 overexpression in mouse fibroblasts inhibited Rac pathway activation and matrix metalloproteinase-9 (MMP-9) expression, highlighting a role for GBP2 in cancer metastasis (6). Conversely, in glioma cells, increased GBP2 enhances proliferation and migration, likely through epidermal growth factor receptor (EGFR) signaling and direct interaction with kinesin superfamily member 22 (KIF22) (7). Given its dual role in immune response and cancer, GBP2 represents a potential therapeutic target.
GBPs are IFN-inducible proteins widely distributed among eukaryotes and are involved in innate immune response and inflammasome activation (3,4). During infection, GBP2 can be localized to pathogen-containing vacuoles and act as a positive regulator of inflammasome assembly. GBP2 promotes lysis of pathogen-containing vacuoles and recruits proteins that mediate bacterial lysis. This process makes ligands available that are detected by inflammasomes, such as lipopolysaccharide (LPS), which activates the non-canonical caspases (through caspase-4 and caspase-11), or double-stranded DNA (dsDNA), which activates inflammasome assembly through AIM2 (5).
In addition to GBP2’s role in immune response, recent work has explored the role of GBP2 in tumor growth and progression (6-8). Increased GBP2 expression is associated with a better prognosis in breast and colon cancers and may result in increased T cell defense against some tumor types (6,7). GBP2 overexpression in mouse fibroblasts inhibited Rac pathway activation and matrix metalloproteinase-9 (MMP-9) expression, highlighting a role for GBP2 in cancer metastasis (6). Conversely, in glioma cells, increased GBP2 enhances proliferation and migration, likely through epidermal growth factor receptor (EGFR) signaling and direct interaction with kinesin superfamily member 22 (KIF22) (7). Given its dual role in immune response and cancer, GBP2 represents a potential therapeutic target.
- Kim, B.H. et al. (2011) Science 332, 717-21.
- Schelle, L. et al. (2023) Med Microbiol Immunol 212, 141-152.
- Braun, E. et al. (2019) Cell Rep 27, 2092-2104.e10.
- Kim, B.H. et al. (2016) Nat Immunol 17, 481-9.
- Dickinson, M.S. et al. (2023) Proc Natl Acad Sci USA 120, e2216028120.
- Zhang, J. et al. (2017) Cell Death Dis 8, e3151.
- Wang, H. et al. (2022) J Immunother Cancer 10, e004302. doi: 10.1136/jitc-2021-004302.
- Ren, Y. et al. (2022) Cell Death Discov 8, 208.
Alternate Names
GBP-2; GBP2; GTP-binding protein 2; Guanine nucleotide-binding protein 2; guanylate binding protein 2; guanylate binding protein 2, interferon-inducible; Guanylate-binding protein 2; HuGBP-2; Interferon-induced guanylate-binding protein 2
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not for Use in Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
KARPAS cell line source: Dr. Abraham Karpas at the University of Cambridge.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.